FDA Approves NovoLog(R) Labeling Update (p NovoLog((R)) is a rapid-acting in...)

FDA Approves NovoLog(R) Labeling Update

Date:7/15/2009

NovoLog((R)) is a rapid-acting insulin analog, meaning it works faster and for a shorter period of time compared with regular human insulin. NovoLog((R)) is also available in FlexPen((R)), the world's #1 selling prefilled insulin pen. Diabetes patients who take NovoLog((R)) can eat within 5-10 minutes of use, rather than the typical 30 minutes required with regular human insulin.

NovoLog((R)) was first approved by the FDA in 2000 and approved for use in pumps in 2001.

Prescribing information for NovoLog((R)) is available by contacting Novo Nordisk or visiting http://www.novolog.com.

About NovoLog (R) (insulin aspart [rDNA origin] injection)

NovoLog (R) is a man-made insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

Important Safety Information

Do not take NovoLog(R) if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in NovoLog(R). If you take too much NovoLog(R) your blood sugar may fall too low.

NovoLog(R) is a fast-acting insulin. You should eat a meal within 5 to 10 minutes after using NovoLog(R) to avoid low blood sugar. Do not inject NovoLog(R) if you do not plan to eat right after using NovoLog(R). Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take NovoLog(R).

Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.

Do not mix NovoLog(R) with any other insulins when used in a pump or with any insulins other than NPH when used with injecti
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Fitness Management Group, Inc. Approves Sale of the Company
2. Cardinal Health Board of Directors Approves CareFusion Spinoff
3. Video: FDA Approves Hologics Adiana(R) Permanent Contraception System
4. European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
5. FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
6. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
7. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
8. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
9. ClearWay Minnesota(SM) Board Approves Four Regional Grants
10. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
11. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes

Post Your Comments:

FDA Approves NovoLog(R) Labeling Update(p NovoLog((R)) is a rapid-acting in...),Health